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Background: The effect of sodium nitroprusside (NTP) on myocardial infarct size and myocardial salvage after primary percutaneous coronary 
intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) remains unclear. The aim of this study was to test whether NTP injected 
intracoronary during primary PCI for STEMI reduces infarct size. 
Methods: From October 2006 to May 2009, we randomly assigned 109 patients with STEMI to have primary PCI performed with (NTP group; n= 
56) or without (control group; n= 53) intracoronary NTP injection. NTP (50 to 150 μg) was selectively injected into the infarct-related artery during 
PCI. Risk area was assessed by 123I ß-methyl-p-iodophenyl-pentadecanoic acid (123I-BMIPP) single photon emission computed tomography 
(SPECT) 5 to 7 days after infarction, and infarct size was assessed by 99mTc-tetrofosmin SPECT at 3 months. The primary end point was final infarct 
size. Secondary end points included post-intervention angiographic corrected thrombolysis in myocardial infarction (TIMI) frame count and clinical 
outcomes at 6 months follow-up. 
Results: Two SPECT images (123I-BMIPP and 99mTc-tetrofosmin) were available in 95 (87%) patients. These patients were the basis of the 
intention to treat analysis. The baseline demographic and clinical characteristics were similar between the two study groups including the peak value 
of creatine kinase leakage and the size of area at risk. Final infarct size was not statistically different in the NTP and control groups (16.7±21.5% vs. 
20.2±19.3%, p=0.403). The corrected TIMI frame count after PCI was 24.1±11.9 in the NTP group and 26.8±14.5 in the control group (p=0.332). 
Six-month clinical follow-up data will be presented at the meeting. 
Conclusions: In patients with STEMI, the routine use of NTP during primary PCI dose not seem to improve coronary flow or limit infarct size.
